Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trial

A year after it reported a Phase 2/3 success, Compass Therapeutics on Monday revealed further results for its closely watched bispecific antibody in second-line biliary tract cancer. While the investigational drug succeeded ...